JP5780693B2 - 免疫原性組成物 - Google Patents

免疫原性組成物 Download PDF

Info

Publication number
JP5780693B2
JP5780693B2 JP2008546433A JP2008546433A JP5780693B2 JP 5780693 B2 JP5780693 B2 JP 5780693B2 JP 2008546433 A JP2008546433 A JP 2008546433A JP 2008546433 A JP2008546433 A JP 2008546433A JP 5780693 B2 JP5780693 B2 JP 5780693B2
Authority
JP
Japan
Prior art keywords
protein
seq
polypeptide
sbi
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008546433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009520758A5 (OSRAM
JP2009520758A (ja
Inventor
カスタード，シンディ
ネイト，セシル，アンヌ
プールマン，ジャン
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2009520758A publication Critical patent/JP2009520758A/ja
Publication of JP2009520758A5 publication Critical patent/JP2009520758A5/ja
Application granted granted Critical
Publication of JP5780693B2 publication Critical patent/JP5780693B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008546433A 2005-12-21 2006-12-19 免疫原性組成物 Expired - Fee Related JP5780693B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526038A GB0526038D0 (en) 2005-12-21 2005-12-21 Immunogenic composition
GB0526038.5 2005-12-21
PCT/EP2006/069944 WO2007071692A2 (en) 2005-12-21 2006-12-19 Immunogenic composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013117514A Division JP2013215197A (ja) 2005-12-21 2013-06-04 免疫原性組成物

Publications (3)

Publication Number Publication Date
JP2009520758A JP2009520758A (ja) 2009-05-28
JP2009520758A5 JP2009520758A5 (OSRAM) 2010-02-12
JP5780693B2 true JP5780693B2 (ja) 2015-09-16

Family

ID=35840898

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008546433A Expired - Fee Related JP5780693B2 (ja) 2005-12-21 2006-12-19 免疫原性組成物
JP2013117514A Pending JP2013215197A (ja) 2005-12-21 2013-06-04 免疫原性組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013117514A Pending JP2013215197A (ja) 2005-12-21 2013-06-04 免疫原性組成物

Country Status (7)

Country Link
US (2) US20080311146A1 (OSRAM)
EP (1) EP1962890B1 (OSRAM)
JP (2) JP5780693B2 (OSRAM)
CA (1) CA2634898A1 (OSRAM)
ES (1) ES2558703T3 (OSRAM)
GB (1) GB0526038D0 (OSRAM)
WO (1) WO2007071692A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021215462A1 (ja) * 2020-04-23 2021-10-28 ブライトパス・バイオ株式会社 改良ペプチドワクチン

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610776D0 (en) * 2006-05-31 2006-07-12 Univ Bath Novel applications for staphylococcus aureus Sbi protein
US7691608B2 (en) 2006-12-06 2010-04-06 Repligen Corporation Nucleic acids encoding recombinant protein A
ES2784957T3 (es) 2009-04-03 2020-10-02 Univ Chicago Composiciones y métodos relacionados con variantes de la proteína A (SPA)
CA3154626A1 (en) 2009-04-14 2010-10-21 Glaxosmithkline Biologicals S.A. Compositions for immunising against staphylococcus aureus
AU2010352695B2 (en) 2009-09-30 2014-08-21 Glaxosmithkline Biologicals S.A. Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
BR112012010223A2 (pt) 2009-10-30 2016-12-06 Novartis Ag purificação de staphylococcus aureus tipo 5 e tipo 8 sacarídeos capsulares
BR112013000097B1 (pt) 2010-07-02 2022-02-01 The University Of Chicago Polipeptídeo imunogênico isolado, composição imunogênica e seu uso
EP2614074A1 (en) * 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
EP2793944B1 (en) 2011-12-23 2025-10-08 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
CN102698260B (zh) * 2012-04-20 2013-09-25 西北农林科技大学 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用
WO2015073801A1 (en) * 2013-11-14 2015-05-21 Duke University Tetanus toxoid and ccl3 improve dc vaccines
EP3076998A1 (en) 2013-12-04 2016-10-12 Glycovaxyn AG Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli
CN103694322B (zh) * 2013-12-09 2016-08-17 成都欧林生物科技股份有限公司 金黄色葡萄球菌SpA5突变体及其制备方法和应用
SG11201606887WA (en) 2014-03-26 2016-09-29 Glaxosmithkline Biolog Sa Mutant staphylococcal antigens
GB201619965D0 (en) * 2016-11-25 2017-01-11 Univ Of Bath The Immunogenic compositions comprising sbi protein and uses thereof
GB201802339D0 (en) 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2024129976A2 (en) * 2022-12-14 2024-06-20 Scribe Therapeutics Inc. Particle delivery systems

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571514A (en) * 1987-06-01 1996-11-05 Alfa Laval Ab Fibronectin binding protein as well as its preparation
SE9704141D0 (sv) * 1997-11-12 1997-11-12 Sbl Vaccin Ab New protein and nucleotide sequence, encoding said protein
WO2000012131A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Multicomponent vaccines
WO2000012132A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
CA2344166C (en) 1998-09-14 2008-11-18 Nabi Compositions of .beta.-glucans and specific igiv
US7098383B2 (en) * 2000-12-19 2006-08-29 Sembiosys Genetics Inc. Methods for the production of multimeric immunoglobulins, and related compositions
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP1601381A2 (en) * 2003-03-07 2005-12-07 Wyeth Holdings Corporation Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
US20050101623A1 (en) * 2003-07-23 2005-05-12 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
HRP20100240T1 (hr) * 2003-07-24 2010-09-30 Merck Sharp & Dohme Corp. Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus
AU2005287505A1 (en) * 2004-09-22 2006-03-30 Biosynexus Incorporated Staphylococcal immunogenic compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021215462A1 (ja) * 2020-04-23 2021-10-28 ブライトパス・バイオ株式会社 改良ペプチドワクチン

Also Published As

Publication number Publication date
WO2007071692A2 (en) 2007-06-28
EP1962890B1 (en) 2015-11-11
EP1962890A2 (en) 2008-09-03
ES2558703T3 (es) 2016-02-08
WO2007071692A3 (en) 2007-09-13
CA2634898A1 (en) 2007-06-28
JP2009520758A (ja) 2009-05-28
JP2013215197A (ja) 2013-10-24
US20080311146A1 (en) 2008-12-18
GB0526038D0 (en) 2006-02-01
US20150125481A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
JP2013215197A (ja) 免疫原性組成物
JP6594385B2 (ja) 免疫原性組成物
AU2018201768B2 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
EP1185297B1 (en) Streptococcus pneumoniae proteins and vaccines
JP2013501027A (ja) 抗原性黄色ブドウ球菌タンパク質を含む免疫原性組成物
KR102393038B1 (ko) OspA의 돌연변이체 단편 및 이에 관련된 방법 및 용도
RU2757426C2 (ru) Иммунногенный слитый белок
JP2010057501A (ja) 肺炎球菌感染を治療または予防するための組成物および方法
JP5922573B2 (ja) ブドウ球菌クランピング因子ａの変異体を含む免疫原性組成物
US6887480B1 (en) Streptococcus pneumoniae proteins and vaccines
JP6401148B2 (ja) 抗原および抗原の組み合わせ
US20110171224A1 (en) PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
HK1250933A1 (en) Immunogenic fusion protein
HK1175704A (en) Immunogenic composition for use in vaccination against staphylococcei

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130604

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130613

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20130802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150714

R150 Certificate of patent or registration of utility model

Ref document number: 5780693

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees